NVZMY vs. VRTX
NVZMY (Novozymes AS) and VRTX (Vertex Pharmaceuticals Incorporated) are both stocks. NVZMY operates in Specialty Chemicals (Basic Materials), while VRTX operates in Biotechnology (Healthcare). Over the past 10 years, NVZMY returned 3.16%/yr vs 16.38%/yr for VRTX. At a 0.17 correlation, their price movements are largely independent.
Performance
NVZMY vs. VRTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVZMY achieves a -9.56% return, which is significantly lower than VRTX's -5.52% return. Over the past 10 years, NVZMY has underperformed VRTX with an annualized return of 3.16%, while VRTX has yielded a comparatively higher 16.38% annualized return.
NVZMY
- 1D
- -1.49%
- 1M
- -8.79%
- YTD
- -9.56%
- 6M
- -5.39%
- 1Y
- -17.70%
- 3Y*
- 6.85%
- 5Y*
- -3.38%
- 10Y*
- 3.16%
VRTX
- 1D
- 0.76%
- 1M
- -0.35%
- YTD
- -5.52%
- 6M
- -7.51%
- 1Y
- -4.06%
- 3Y*
- 8.67%
- 5Y*
- 15.33%
- 10Y*
- 16.38%
NVZMY vs. VRTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVZMY Novozymes AS | -9.56% | 14.29% | 3.97% | 12.42% | -38.46% | 46.93% | 18.10% | 10.28% | -20.91% | 69.59% |
VRTX Vertex Pharmaceuticals Incorporated | -5.52% | 12.58% | -1.03% | 40.90% | 31.50% | -7.08% | 7.94% | 32.13% | 10.58% | 103.42% |
Correlation
The correlation between NVZMY and VRTX is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.11 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jul 16, 2007 | 0.17 |
Fundamentals
NVZMY:
$26.51B
VRTX:
$109.78B
NVZMY:
$1.28
VRTX:
$16.87
NVZMY:
44.44
VRTX:
25.40
NVZMY:
2.41
VRTX:
8.99
NVZMY:
2.42
VRTX:
4.15
NVZMY:
$11.07B
VRTX:
$12.26B
NVZMY:
$5.79B
VRTX:
$10.57B
NVZMY:
$3.39B
VRTX:
$5.19B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVZMY vs. VRTX — Risk / Return Rank
NVZMY
VRTX
NVZMY vs. VRTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novozymes AS (NVZMY) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NVZMY | VRTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.60 | ||
| Sortino ratioReturn per unit of downside risk | -1.02 | ||
| Omega ratioGain probability vs. loss probability | 0.89 | 1.01 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | -0.60 | -0.17 | -0.43 |
| Martin ratioReturn relative to average drawdown | -1.04 | -0.37 | -0.68 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NVZMY | VRTX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.72 | -0.12 | -0.60 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.12 | 0.53 | -0.66 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.12 | 0.50 | -0.38 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.08 | 0.25 | -0.33 |
Drawdowns
NVZMY vs. VRTX - Drawdown Comparison
The maximum NVZMY drawdown since its inception was -86.29%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for NVZMY and VRTX.
Loading charts...
Drawdown Indicators
| NVZMY | VRTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.29% | -91.77% | +5.48% |
Max Drawdown (1Y)Largest decline over 1 year | -29.64% | -23.56% | -6.08% |
Max Drawdown (3Y)Largest decline over 3 years | -29.64% | -29.07% | -0.57% |
Max Drawdown (5Y)Largest decline over 5 years | -51.86% | -29.07% | -22.79% |
Max Drawdown (10Y)Largest decline over 10 years | -51.86% | -41.60% | -10.26% |
Current DrawdownCurrent decline from peak | -61.08% | -17.11% | -43.97% |
Average DrawdownAverage peak-to-trough decline | -57.41% | -37.70% | -19.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.02% | 11.14% | +5.88% |
Volatility
NVZMY vs. VRTX - Volatility Comparison
Novozymes AS (NVZMY) and Vertex Pharmaceuticals Incorporated (VRTX) have volatilities of 7.10% and 7.03%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVZMY | VRTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.10% | 7.03% | +0.07% |
Volatility (6M)Calculated over the trailing 6-month period | 16.86% | 21.69% | -4.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.67% | 33.88% | -9.21% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 27.71% | 28.90% | -1.19% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 27.13% | 32.82% | -5.69% |
Dividends
NVZMY vs. VRTX - Dividend Comparison
NVZMY's dividend yield for the trailing twelve months is around 1.79%, while VRTX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVZMY Novozymes AS | 1.79% | 1.51% | 1.03% | 2.68% | 1.68% | 0.69% | 0.91% | 1.03% | 1.10% | 1.64% | 0.95% | 0.60% |
VRTX Vertex Pharmaceuticals Incorporated | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NVZMY vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Novozymes AS and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVZMY vs. VRTX - Profitability Comparison
NVZMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a gross profit of 644.63M and revenue of 1.14B. Therefore, the gross margin over that period was 56.7%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.59B and revenue of 2.99B. Therefore, the gross margin over that period was 86.9%.
NVZMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported an operating income of 272.81M and revenue of 1.14B, resulting in an operating margin of 24.0%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.14B and revenue of 2.99B, resulting in an operating margin of 38.1%.
NVZMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novozymes AS reported a net income of 202.37M and revenue of 1.14B, resulting in a net margin of 17.8%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.03B and revenue of 2.99B, resulting in a net margin of 34.5%.
Frequently Asked Questions
NVZMY and VRTX have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVZMY has higher volatility (7.10%) compared to VRTX (7.03%). In terms of maximum drawdown, NVZMY dropped -86.29% vs VRTX's -91.77%.
VRTX currently has the higher Sharpe Ratio (-0.12 vs -0.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVZMY and VRTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer